Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Hepatitis vaccines.

R S Koff1

  • 1Department of Medicine, Division of Digestive Disease and Medicine, University of Massachusetts Medical School, Worcester, Massachusetts, USA.

Infectious Disease Clinics of North America
|April 17, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Review article: the efficacy and safety of sofosbuvir, a novel, oral nucleotide NS5B polymerase inhibitor, in the treatment of chronic hepatitis C virus infection.

Alimentary pharmacology & therapeutics·2014
Same author

Review article: vaccination and viral hepatitis - current status and future prospects.

Alimentary pharmacology & therapeutics·2007
Same author

Prevention of hepatitis C virus infection.

Clinics in liver disease·2004
Same author

Terbinafine-induced hepatitis and pancytopenia.

Digestive diseases and sciences·2001
Same author

Risks associated with hepatitis A and hepatitis B in patients with hepatitis C.

Journal of clinical gastroenterology·2001
Same author

Cost-effectiveness of combined interferon and ribavirin versus interferon alone.

Clinics in liver disease·2001
Same journal

Prevention and Control of Clostridioides difficile Infection for the Infectious Diseases Clinician.

Infectious disease clinics of North America·2026
Same journal

Infection Control Strategies to Prevent Emergence and Transmission of Resistant Gram-Negative Bacteria.

Infectious disease clinics of North America·2026
Same journal

Preventing the Spread of Tuberculosis in Health Care Settings.

Infectious disease clinics of North America·2026
Same journal

Threats to Success: Principles of Infection Prevention and Control in Health Care Settings, Part 2: Device and Pathogen Management.

Infectious disease clinics of North America·2026
Same journal

Ventilator-Associated Events: Surveillance and Prevention.

Infectious disease clinics of North America·2026
Same journal

Nosocomial Fungal Infections: Epidemiology, Control Strategies, and Prevention of Candida and Other Yeasts.

Infectious disease clinics of North America·2026
See all related articles

Highly effective inactivated Hepatitis A virus (HAV) and Hepatitis B virus (HBV) vaccines are available, but challenges like vaccine nonresponsiveness and the need for universal childhood immunization remain for widespread control.

Area of Science:

  • Hepatology and Vaccinology
  • Viral Hepatitis Prevention and Control

Background:

  • Significant progress has been made in developing inactivated Hepatitis A virus (HAV) vaccines and recombinant Hepatitis B surface antigen (HBsAg) subunit Hepatitis B virus (HBV) vaccines.
  • Current vaccination strategies for HAV and HBV face challenges that limit their effectiveness in reducing overall infection rates.

Purpose of the Study:

  • To review the current status and challenges of vaccines for viral hepatitis.
  • To highlight the need for expanded immunization programs and address remaining obstacles in viral hepatitis vaccine development and implementation.

Main Methods:

  • Review of existing literature on HAV, HBV, HDV, HEV, and HCV vaccines.
  • Analysis of current immunization recommendations and their impact on infection rates.

Related Experiment Videos

  • Identification of challenges associated with vaccine efficacy, duration of protection, and development of new vaccines.

    • Main Results:

    • Highly effective inactivated HAV and recombinant HBsAg subunit HBV vaccines have been developed.
    • HAV vaccination is currently targeted at high-risk groups, limiting dramatic infection rate reduction without universal childhood programs.
    • Routine HBV vaccination reduces incidence but faces challenges from vaccine nonresponsiveness and escape mutants; lifelong protection for both is undetermined.

    Conclusions:

    • Universal childhood immunization for HAV is crucial for significantly reducing infection rates.
    • While routine HBV vaccination is effective, addressing nonresponsiveness and escape mutants is necessary.
    • Vaccines for Hepatitis D virus (HDV), Hepatitis E virus (HEV), and Hepatitis C virus (HCV) are not yet available, representing areas for future research and development.